COVID-19 update, 20 Mar

Drug combination works in hospitalized patients!

A small French study shows that an old malaria drug, hydroxychloroquine (HCQ) combined with (AZ) azithromycin.

The graph below shows the percent of patients with a nasal swab that contains the virus.

Black line (control), no change over six days.

Blue line, HCQ alone, nice reduction that is different from control on day 3 but is not cured by day six.

Green line, HCQ plus AZ together, better reduction than HCQ alone and NO VIRUS by day 5!

Caveat: a 20 patient study so results may differ on a big scale but this is a major breakthrough.

Note: my previous analysis of HCQ based on test tube data was that it would fail. I am glad it was tested!

Here is the paper if you want details.

About Dr. Quay

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and COVID-19 therapeutics.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, and a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times.

He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passions are big medical problems: stopping the COVID-19 pandemic and preventing the two million breast cancers in the world each year.

The COVID-19 HOPE Clinical Trial​